This inventor holds 1 USPTO granted patent. Top assignee: Astrazeneca Ab. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Innovations in Obesity Treatment: The Contributions of Mario Maidonado
Introduction
Mario Maidonado, an innovative inventor based in Basel, Switzerland, has made significant strides in the field of obesity treatment. With a focus on utilizing SGLT2 inhibitors, his work reflects a commitment to advancing medical science and improving patient outcomes.
Latest Patents
Maidonado holds a patent for "Methods for treating obesity employing an SGLT2 inhibitor." This groundbreaking patent outlines methods for treating obesity or facilitating weight loss in a mammalian subject by administering a therapeutically effective amount of an SGLT2 inhibitor, either alone or in combination with another anti-obesity agent. Furthermore, the patent details a pharmaceutical composition that includes an SGLT2 inhibitor along with an appropriate carrier. This innovation holds promise for addressing obesity, a condition that affects millions globally.
Career Highlights
Mario Maidonado is associated with AstraZeneca AB, a leading pharmaceutical company known for its research and development in various therapeutic areas. His work within the organization focuses on pioneering treatments that could shape the future of obesity management.
Collaborations
In his professional journey, Maidonado has collaborated with notable colleagues such as William N. Washburn and Jean Whaley. These partnerships reflect a collective effort to innovate and advance treatment options in the medical field, harnessing a diverse range of expertise and perspectives.
Conclusion
Mario Maidonado's contributions to the medical community, particularly in the realm of obesity treatment, underscore the importance of innovation and collaboration in the pursuit of improved health solutions. His patented methods for utilizing SGLT2 inhibitors mark a significant step forward in addressing one of today's pressing health challenges.